logo

Apellis Pharmaceuticals, Inc. (APLS)



Trade APLS now with
  Date
  Headline
9/18/2019 8:11:06 AM Apellis Pharma Publishes Phase 2 Study In Ophthalmology Highlights Efficacy And Safety Data Of Intravitreal APL-2
7/22/2019 7:13:40 AM Apellis Pharma Appoints Lucia Celona As Chief People Officer
6/15/2019 10:57:08 AM Apellis Pharma Presents Data From Ongoing APL-2 Phase 2 Study At 24th EHA Congress
3/7/2019 7:14:35 AM Apellis Pharma Prices Public Offering Of 6 Mln Shares $17/Shr
1/31/2019 9:03:49 AM Apellis Appoints Thomas Lackner As SVP, Head Of Europe
12/20/2018 7:12:13 AM Apellis Pharma Provides Update On Its Phase 3 Program For Patients With Geographic Atrophy
9/12/2018 7:36:00 AM Apellis Begins Phase 3 Clinical Program For APL-2 In Patients With Geographic Atrophy
7/31/2018 4:42:19 PM Apellis Pharmaceuticals Q2 Loss/share $0.61 Vs. Loss $1.44 Year Ago
7/24/2018 9:04:00 AM Apellis’ APL-2 Receives Fast Track Designation From FDA For Treatment Of Patients With Geographic Atrophy
6/26/2018 7:31:36 AM Apellis Pharma Provides Update On Two Phase Ib Trials For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
4/30/2018 4:12:20 PM Apellis Pharmaceuticals Q1 Loss/share $1.07 Vs. Loss $0.43 Year Ago
4/18/2018 9:51:19 PM Apellis Pharma Prices Underwritten Public Offering Of 5.50 Mln Shares At $25.50/shr
4/16/2018 5:22:41 PM Apellis Pharmaceuticals Announces Proposed Offering Of Common Stock
4/12/2018 9:52:55 AM B. Riley FBR Cuts Apellis Pharmaceuticals, Inc. (APLS) To Neutral From Buy With $27 Price Target